Results 131 to 140 of about 351,966 (398)

Leukemia and risk of stroke: a Mendelian randomization analysis

open access: yesBMC Neurology
Background Observational studies suggest an association between leukemia and stroke, but causality remains unclear. Certain leukemia types may increase stroke risk, but variations exist in stroke and mortality rates across leukemia subtypes.
Xiaoyao Yi   +4 more
doaj   +1 more source

Chromatin Redistribution of the DEK Oncoprotein Represses hTERT Transcription in Leukemias

open access: yesNeoplasia: An International Journal for Oncology Research, 2014
Although numerous factors have been found to modulate hTERT transcription, the mechanism of its repression in certain leukemias remains unknown. We show here that DEK represses hTERT transcription through its enrichment on the hTERT promoter in cells ...
Maroun Karam   +14 more
doaj   +1 more source

Automated classification of blasts in acute leukemia blood samples using HMLP network [PDF]

open access: yes, 2011
This paper presents a study on classification of blasts in acute leukemia blood samples using artificial neural network.In acute leukemia there are two major forms that are acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL).Six ...
Abdul Nasir, A.S.   +3 more
core  

Efficient Segmentation of Lymphoblast in Acute Lymphocytic Leukemia [PDF]

open access: hybrid, 2021
Syed Ijaz Ur Rahman   +4 more
openalex   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

open access: yesAdvanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu   +11 more
wiley   +1 more source

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

open access: yesAdvanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen   +11 more
wiley   +1 more source

Bloodstream infections in pediatric patients with acute leukemia: Emphasis on gram-negative bacteria infections

open access: yesJournal of Microbiology, Immunology and Infection, 2017
Background/Purpose: Acute leukemia is the most common pediatric hematological malignancy. Bloodstream infections (BSIs) are severe complications in these patients during chemotherapy.
Fu-Chun Kuo   +7 more
doaj   +1 more source

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]

open access: yes, 2001
The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A   +9 more
core  

Dynamic Decoration of DNA Scaffolds for High‐Resolution Cancer Cell Subtyping

open access: yesAdvanced Science, EarlyView.
This study presents a dual‐mode imaging platform that utilizes self‐assembly and disassembly of DNA scaffolds for high‐resolution cancer cell detection. The structural rigidity of DNA scaffolds effectively prevents cellular internalization for over 300 min.
Xiaolin Hu   +15 more
wiley   +1 more source

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. [PDF]

open access: yes, 2009
We observed that high-dose methylprednisolone (HDMP) and rituximab was well tolerated and had promising activity when used in combination to treat patients with fludarabine-refractory chronic lymphocytic leukemia (CLL).
Bole, J   +6 more
core  

Home - About - Disclaimer - Privacy